Denali Therapeutics Inc. — Director's Dealing 2021

Feb 17, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2021-02-11

Reporting Person: Watts Ryan J. (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-11	Common Stock	S	8513	$70.172	Disposed	2325036	Indirect
2021-02-11	Common Stock	S	960	$71.469	Disposed	2324076	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	156691	Direct

Footnotes

F1: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units.

F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $69.71 to $70.66 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F3: Includes 19,696 shares acquired pursuant to vesting of restricted stock units and issued directly to the Watts Family 2015 Trust dated July 7, 2015.

F4: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.

F5: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $71.03 to $71.90 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F6: The Reporting Person has reported prior awards of restricted stock units in Table II of Form 4. This total reported in Column 5 includes 156,691 previously reported restricted stock units.